Slusser Associates

RM Global BioAccess Fund Management is dedicated to accelerating innovative science to develop new medicines through strategic partnerships with forward-thinking companies. The fund focuses on transformative technologies aimed at addressing significant unmet medical needs in oncology, rare diseases, central nervous system (CNS) disorders, and cardiology. With a commitment to investing in early-stage companies, the Global BioAccess Fund provides essential capital to support investigational new drug (IND) submissions and clinical trials. Their mission centers around fostering advancements in therapeutics and devices that can ultimately improve patient outcomes in critical health areas. Generated from the website

RM Global BioAccess Fund Management is dedicated to accelerating the development of innovative medicines by partnering with forward-thinking companies. The fund focuses on investing in transformative technologies that address unmet medical needs across various fields, including oncology, cardiovascular, central nervous system (CNS), and rare diseases. Specializing in early-stage companies, the Global BioAccess Fund provides crucial capital to support Investigational New Drug (IND) submissions and clinical trials. By funding groundbreaking therapeutics and devices, the fund aims to contribute significantly to the advancement of healthcare solutions for serious medical conditions. Generated from the website